UCLA Center for Behavioral and Addiction Medicine
Los Angeles, California, 90024, United States
NCT Number: NCT05006846
With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America's most widespread behavioral public health problem. Medication-assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. The Opioid Addiction Recovery Support (OARS), comprised of a healthcare team portal connected to a patient mobile application, provides opioid-related education, promotes connectedness with clinicians, and tracks MAT treatment progress. This study will conduct interviews with patients that will inform optimal design of OARS, assess the efficacy of OARS in improving MAT outcomes in primary care settings, and evaluate the sustainability and return on investment.
It joins an outstanding scientific team at University of California, Los Angeles and a small business that has developed, Opioid Addiction Recovery Support (OARS) -- a software platform that by integrating with the Electronic Health Record (EHR) improves clinical management of patients by primary care providers (PCPs) treating patients with OUD using MAT. OARS platform uses a dashboard to show the real-time measurement of patient achievements in recovery. It provides opportunities for patients to interact with their PCPs, allowing for better connection to and support from their PCPs. OARS platform features artificial intelligence to analyze information from the EHR and from patients to provide a relapse risk assessment for patients receiving MAT for OUD, an innovation that sets OARS apart from other software solutions. The goal of Phase 1 was to modify the OARS platform for use in primary care settings by conducting interviews with Primary Care Physicians (PCPs) (N=20) and their patients with OUD (N=40) in primary care settings to collect data on feasibility and acceptability of engaging with OARS to inform the user-centered design of OARS.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Los Angeles, California, 90024, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
Other names: OARS
Time frame: From week 1 to week 4.
Frequency of days of engagement per week and use of interactive features does not reduce over 20%.
Time frame: From week 1 to week 4.
Frequency of days of engagement per week and use of interactive features does not reduce over 20%.
Time frame: At week 4.
No more than 20% of qualitative mentions that describe barriers or dissatisfactions with using OARS platform).
Time frame: At week 4.
No more than 20% of qualitative mentions that describe barriers or dissatisfactions with using OARS platform).
Time frame: At week 4.
The System Usability Scale (SUS) is a tool for measuring the usability, consisting of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree.
Time frame: At week 4.
The System Usability Scale (SUS) is a tool for measuring the usability, consisting of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree.
Q2i, LLC
Industry
Technology Improving Success of Medication-Assisted Treatment in Primary Care - Phase 1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04632238
Chemically-Induced Disorders, Mental Disorders
Blauvelt, New York, United States
View Trial DetailsNCT04180020
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT04808479
Chemically-Induced Disorders, Mental Disorders
Tarzana, California, United States
View Trial DetailsNCT04104022
Chemically-Induced Disorders, Mental Disorders
Burlington, Vermont, United States
View Trial Details